Welcome to our dedicated page for QIAGEN N.V. news (Ticker: QGEN), a resource for investors and traders seeking the latest updates and insights on QIAGEN N.V. stock.
QIAGEN N.V. (symbol: QGEN) is a leading global provider of sample-to-insight solutions that transform biological materials into valuable molecular insights. The company's sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. Its assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases from QIAGEN interpret data to report relevant, actionable insights. Automation solutions tie these components together in seamless and cost-effective molecular testing workflows.
QIAGEN serves a diverse customer base of over 500,000 worldwide in sectors such as molecular diagnostics (human healthcare), applied testing (forensics, veterinary testing, and food safety), pharma (pharmaceutical and biotechnology companies), and academia (life sciences research). As of June 30, 2015, the company employed approximately 4,400 people across 35 locations globally. Additional information can be found on their website at http://www.qiagen.com.
QIAGEN's proprietary sample and assay technology enables the extraction, purification, amplification, and interpretation of DNA, RNA, and proteins. The company's revenue is almost evenly split between life sciences and molecular diagnostics applications, with nearly 90% of its revenue derived from consumables and the remaining from instrumentation and related services. The largest portion of QIAGEN's revenue comes from the Americas (over 45% of 2022 sales), followed by EMEA (nearly 35%), and Asia-Pacific (nearly 20%).
Recent achievements include:
- Q1 2024 net sales of $459 million (-5% at actual rates, -5% at constant exchange rates, CER), with a diluted EPS of $0.36 and an adjusted diluted EPS of $0.46. The net sales at CER of $462 million were ahead of the outlook for at least $455 million CER, and the adjusted diluted EPS of $0.47 CER was ahead of the $0.44 CER outlook.
- Strong operating cash flow rose by 85% to $133 million versus Q1 2023.
- The QCI Secondary Analysis software, integrated with QCI Interpret, facilitates high-throughput secondary analysis of clinical next-generation sequencing data.
- Collaborations aimed at creating novel digital PCR assays to improve DNA analysis in forensics and human identification.
- Introduction of the QIAstat-Dx Respiratory Panel Plus for accurate diagnosis of respiratory infections, capable of generating results in about one hour with minimal hands-on time.
- Enhancements to the QIAGEN Clinical Insight Interpret platform, which has processed over 4 million NGS patient test cases for oncology and hereditary diseases worldwide.
- New QIAcuity digital PCR Custom Assay Design Tool for copy number variation analysis, complementing the company's existing assay offerings.
QIAGEN continues to innovate and maintain its leading position in the molecular diagnostics and life sciences industries. The company's ongoing efforts to expand its product offerings and enhance its technologies ensure that it remains a trusted partner for researchers and healthcare providers worldwide.
QIAGEN has launched Ingenuity Pathway Analysis (IPA) Interpret, an AI-powered extension designed to enhance the interpretation of complex biological data. The new feature builds upon IPA's extensively curated knowledge base, which has over 50,000 citations, to help researchers understand gene involvement in diseases, biological processes, and drug responses.
IPA Interpret automatically analyzes gene expression datasets, identifying key biological processes, pathways, and networks, presenting results in a shareable web-page format. The tool combines human expertise with AI and Natural Language Processing to ensure reliable data analysis and causal relationships. This launch follows QIAGEN's recent AI initiatives, including an AI-driven biomedical knowledgebase release in early 2024 and AI enhancements to QIAGEN Clinical Insight Interpret in late 2023.
QIAGEN has announced reaching over 1,000 placements of its EZ2 Connect automated sample preparation instrument, contributing to a global installed base exceeding 5,500 EZ series instruments. Launched in 2021, the system automates nucleic acid purification, reducing hands-on time while maintaining high precision.
The company has expanded its portfolio with the launch of EZ2 PowerFecal Pro DNA/RNA Kit for gut microbiome research, requiring only 27 minutes of hands-on time compared to 45+ minutes for similar kits. The comprehensive EZ2 Connect portfolio supports various applications including diagnostics, genomics, cancer research, and forensics, with additional kits planned for 2025.
QIAGEN announced plans to relocate its QIAstat-Dx operations to a new 8,000-square-meter site in Esplugues de Llobregat, Barcelona, set to open in early 2026. The facility will support the entire value chain for the QIAstat-Dx system, which performs syndromic testing for infectious diseases and precision medicine applications. The site will include R&D, manufacturing, sales, marketing, and regulatory operations, featuring digitalized production lines and LEED Platinum certification. The expansion aims to strengthen QIAGEN's diagnostic capabilities and support recent partnerships with Eli Lilly and AstraZeneca. The QIAstat-Dx system currently has FDA clearance for four panels and CE-marking for two panels under IVDR.
QIAGEN has launched two new tools for customizing microbial analysis solutions: a first-of-its-kind Custom dPCR Microbial Assays design tool and QIAseq xHYB Custom Microbial Panels. The dPCR tool enables customized primer and probe design for bacterial, fungal, and viral targets, while the NGS panels allow comprehensive genome coverage for improved microbial detection. These additions complement QIAGEN's existing portfolio of over 700 digital PCR assays for microbial targets, accessible through the GeneGlobe platform. The new tools enhance capabilities in applications ranging from wastewater testing to food production and human pathogen analysis.
QIAGEN (NYSE: QGEN) has announced a three-year collaboration with McGill University Centre for Microbiome Research to advance microbiome sciences. The partnership will focus on DNA extraction from low microbial biomass samples and anaerobic culturing protocols, targeting the $1.8 billion North American market. McGill will serve as a beta-testing site for new QIAGEN microbiome solutions and receive reagents for research across microbiology and genomic processing workflows. The collaboration aims to generate evidence-based knowledge for medicine and public health while supporting innovation in understanding how microbial communities impact human health and ecosystems.
QIAGEN reported strong Q3 2024 results with net sales of $502 million, representing a 5% increase at actual rates and 6% at constant exchange rates (CER), exceeding the outlook of $495 million CER. The company achieved a 29.6% adjusted operating income margin, up 3 percentage points from Q3 2023. Free cash flow increased 73% to $364 million in the first nine months of 2024. Based on solid performance, QIAGEN reaffirmed its FY 2024 net sales outlook of at least $1.985 billion CER and increased its adjusted diluted EPS outlook to at least $2.19 CER from the previous $2.10 CER.
QIAGEN has received FDA clearance for its QIAstat-Dx Meningitis/Encephalitis Panel, marking its fourth FDA clearance in 2024. The panel enables rapid diagnosis of central nervous system infections, delivering results in about one hour using real-time PCR technology, compared to traditional methods requiring 24+ hours. The test simultaneously analyzes common viral, bacterial, and fungal pathogens responsible for community-acquired meningitis/encephalitis. This approval expands QIAGEN's FDA-cleared test menu, which now covers respiratory, gastrointestinal, and central nervous system infections. The system offers unique features including cycle threshold values and amplification curves for enhanced clinical information.
QIAGEN has received FDA clearance for its QIAstat-Dx Respiratory Panel Mini test, marking its third FDA clearance in 2024. The test targets five key respiratory pathogens: influenza A, influenza B, human rhinovirus, RSV, and SARS-CoV-2. It delivers results in about one hour with minimal hands-on time using real-time PCR technology. This complements the previously cleared 21-target QIAstat-Dx Respiratory Panel Plus, offering clinicians flexibility between comprehensive and targeted testing approaches. The Mini panel is specifically designed for outpatient settings, while the Plus panel suits hospitalized patients with severe disease risk factors.
QIAGEN has announced key updates to its sample technologies solutions for non-invasive liquid biopsy applications. These enhancements are designed for use in research and clinical applications such as oncology, prenatal care, and organ transplantation. The updates include:
1. An upgraded EZ1&2 ccfDNA Kit that now supports processing of 24 samples with up to 10 mL of serum or plasma, along with a new urine protocol.
2. New QIAsymphony DSP Circulating DNA Kit (96) and QIAsymphony DSP Circulating DNA Maxi Kit (192) for fully automated extraction of ccfDNA from up to 10mL sample volume.
These updates are designed to improve results when processing larger sample volumes, important for oncology research and diagnostics. The new kits are intended for in-vitro diagnostic (IVD) use, complying with CE-IVDR and FDA regulations.
QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) has announced its plans to release Q3 2024 results and hold a webcast. The press release will be issued on Wednesday, November 6, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. A conference call is scheduled for Thursday, November 7, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time.
Participants have three options to join the conference call: register for a call back connection, dial-in by phone, or access the audio webcast. The company advises joining the event 5-10 minutes before the start time to avoid waiting. A conference call replay will be available after the event. For further information, interested parties can contact IR@qiagen.com.
FAQ
What is the current stock price of QIAGEN N.V. (QGEN)?
What is the market cap of QIAGEN N.V. (QGEN)?
What does QIAGEN N.V. do?
How many employees does QIAGEN N.V. have?
What are QIAGEN's recent financial achievements?
What industries does QIAGEN serve?
What are QIAGEN’s proprietary technologies?
Where can I find more information about QIAGEN?
What are some of QIAGEN's recent innovations?
How is QIAGEN's revenue split?
Which regions contribute most to QIAGEN's revenue?
What is the QIAstat-Dx Respiratory Panel Plus?
